Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales

Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing
and Sales

BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that industry veteran, Aaron Berg, has been promoted
to Senior Vice President, Marketing and Sales.

With more than 25 years of industry experience, Mr. Berg has significant
marketing and sales experience, including six years at Kos Pharmaceuticals
where as Vice President of Marketing and Sales his contributions to the
commercial success of Niaspan^® helped lead to the acquisition of Kos in 2006
by Abbott Laboratories for $3.6 billion. Before joining Kos Pharmaceuticals,
Mr. Berg began his pharmaceutical industry career as a sales representative
with Bristol-Myers Squibb followed by 10 years of increasing commercial
responsibility at Schering-Plough before being recruited by GlaxoSmithKline to
help build its then newly launched diabetes franchise. After Kos
Pharmaceuticals, Mr. Berg's commercial and business development expertise in
lipid therapy led Essentialis, a development-stage company focused on
triglyceride management, to appoint Mr. Berg as President and CEO where he
remained until he was recruited by Amarin at the end of 2012.Mr. Berg joined
Amarin as Vice President, Marketing and Managed Care, which responsibilities
he assumed from the time of launch of Vascepa^® in early 2013.

"On behalf of Amarin and its Board of Directors, it is with great pleasure
that I announce the promotion of Aaron to this important expanded role,"
stated John F. Thero, President and Chief Executive Officer of Amarin.
"Aaron's experience, leadership and dedication since joining Amarin have been
crucial factors in establishing the sales focus, product messaging and managed
care wins that position Vascepa for further growth. I have the utmost
confidence in Aaron's ability to build on these efforts in leading Amarin's
commercial team positively forward in its second year of Vascepa

"I am proud to be a member of the Amarin team and confident in the continued
growth of Vascepa sales," said Mr. Berg. "Vascepa provides physicians and
their patients with a valuable offering for the treatment of severe
hypertriglyceridemia.It is an exciting time to be at Amarin."

About Vascepa^®(icosapent ethyl) capsules

Vascepa^®(icosapent ethyl) capsules, known in scientific literature as
AMR101, is a highly pure-EPAomega-3 prescription product in a 1 gram capsule.

Indications and Usage

  oVascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce
    triglyceride (TG) levels in adult patients with severe (≥500 mg/dL)
  oThe effect of Vascepa on the risk for pancreatitis and cardiovascular
    mortality and morbidity in patients with severe hypertriglyceridemia has
    not been determined.

Important Safety Information for Vascepa

  oVascepa is contraindicated in patients with known hypersensitivity (e.g.,
    anaphylactic reaction) to Vascepa or any of its components and should be
    used with caution in patients with known hypersensitivity to fish and/or
  oThe most common reported adverse reaction (incidence > 2% and greater than
    placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo).


About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit For more information about Amarin visit

Forward-looking statements

This press release contains forward-looking statements, including statements
about Amarin's expectations for commercial growth.These forward-looking
statements are not promises or guarantees and involve substantial risks and
uncertainties. In particular, as disclosed in its previous filings with the
U.S. Securities and Exchange Commission, Amarin's ability to effectively
commercialize Vascepa will depend in part on its ability to create market
demand for Vascepa through education, marketing and sales activities, to
achieve market acceptance of Vascepa, to receive adequate levels of
reimbursement from third-party payers, to develop and maintain a consistent
source of commercial supply at a competitive price, and to obtain and maintain
patent protection and regulatory exclusivity.A further list and description
of these risks, uncertainties and other risks associated with an investment in
Amarin can be found in Amarin's filings with the U.S. Securities and Exchange
Commission, including its most recent Quarterly Report on Form 10-Q. Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and
the public using our company website (, our investor
relations website (, including
but not limited to investor presentations and investor FAQs,Securities and
Exchange Commissionfilings, press releases, public conference calls and
webcasts. The information that we post on these channels and websites could be
deemed to be material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information that we post
on these channels, including our investor relations website, on a regular
basis. This list of channels may be updated from time to time on our investor
relations website and may include social media channels. The contents of our
website or these channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933.

Niaspan^® is trademark of AbbVie Inc.

CONTACT: Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315

company logo
Press spacebar to pause and continue. Press esc to stop.